Protagenic Therapeutics Net Income Over Time
| PTIX Stock | USD 0.40 0.09 18.37% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Protagenic Therapeutics Performance and Protagenic Therapeutics Correlation. Protagenic | Build AI portfolio with Protagenic Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protagenic Therapeutics. Anticipated expansion of Protagenic directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Protagenic Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Protagenic Therapeutics's market price often diverges from its book value, the accounting figure shown on Protagenic's balance sheet. Smart investors calculate Protagenic Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Protagenic Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Protagenic Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Protagenic Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Protagenic Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Protagenic Therapeutics and related stocks such as Salarius Pharmaceuticals, Lipella Pharmaceuticals, and Artelo Biosciences Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LIPO | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.7 K) | (1.9 M) | (2.6 M) | (4.6 M) | (5 M) | (4.5 M) | (4.3 M) |
| ARTL | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.2 K) | (29.7 K) | (234.9 K) | (2.3 M) | (2.2 M) | (4.7 M) | (7.4 M) | (10.1 M) | (9.3 M) | (9.8 M) | (8.8 M) | (8.4 M) |
| INDP | (5.4 M) | (7.6 M) | (5.2 M) | (5.1 M) | (5.7 M) | (7.2 M) | (13.4 M) | (28.9 M) | (43.5 M) | (47.6 M) | (3.6 M) | (7.7 M) | (14.3 M) | (15.4 M) | (15 M) | (13.5 M) | (14.2 M) |
| SLXN | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (195.9 K) | (755.2 K) | (3.2 M) | (4.9 M) | (16.4 M) | (14.8 M) | (14.1 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (15 M) | (13.5 M) | (12.9 M) |
| CARM | (13 M) | (13 M) | (19.8 M) | (19.4 M) | (34.5 M) | (33.5 M) | 1.9 M | (29 M) | (33.7 M) | (107.5 M) | (28.3 M) | (336 K) | (61.2 M) | (86.9 M) | (60.5 M) | (54.4 M) | (57.2 M) |
| SPRC | (1.7 M) | (3.7 M) | (3.5 M) | 59.4 K | (1.9 M) | (2.5 M) | (2 M) | (6.2 M) | (8.5 M) | (5.4 M) | (3.5 M) | (5.8 M) | (2.6 M) | (5.1 M) | (6.3 M) | (5.7 M) | (5.9 M) |
| GTBP | 150 K | (3.7 M) | (5.2 M) | (501 K) | (23.5 M) | (21.5 M) | 9.8 M | (144.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (7.6 M) | (13.2 M) | (11.8 M) | (12.4 M) |
| PBM | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8 M | (51.2 M) | 1 M | 910.6 K | 956.1 K |
Protagenic Therapeutics and related stocks such as Salarius Pharmaceuticals, Lipella Pharmaceuticals, and Artelo Biosciences Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Protagenic Therapeutics financial statement analysis. It represents the amount of money remaining after all of Protagenic Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Protagenic Therapeutics | PTIX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 701 Anacapa Street, |
| Exchange | NASDAQ Exchange |
USD 0.4
Additional Tools for Protagenic Stock Analysis
When running Protagenic Therapeutics' price analysis, check to measure Protagenic Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protagenic Therapeutics is operating at the current time. Most of Protagenic Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protagenic Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protagenic Therapeutics' price. Additionally, you may evaluate how the addition of Protagenic Therapeutics to your portfolios can decrease your overall portfolio volatility.